Sunshine Biopharma Inc (SBFM)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $2.22M
Last updated: Nov 17, 2026 at 11:05 AM ET
Sunshine Biopharma Inc (SBFM) Stock Forecast
Analysts expect Sunshine Biopharma (SBFM) to earn -$39.00 per share in the fiscal year ending Dec 31, 2026, on revenue of $36.75M. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$8.00.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 22.4%.
- Fiscal year ending Dec 31, 2026
- -$39.00
- EPS consensus, revenue $36.75M
- Fiscal year ending Dec 31, 2027
- -$8.00
- EPS consensus, revenue $45.00M
- Next report
- Apr 1, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$39.00 | -$39.00 to -$39.00 | 1 | $36.75M | $36.75M to $36.75M | 1 |
| Dec 31, 2027 | -$8.00 | -$8.00 to -$8.00 | 1 | $45.00M | $45.00M to $45.00M | 1 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$5.92 | N/A | 3 | $10.00M | $9.60M to $10.29M | 3 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 1 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$126.00.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$39.00 | -$126.00 | -$126.00 | -$126.00 | -$126.00 | N/A |
| Fiscal year ending Dec 31, 2027 | -$8.00 | $4.00 | $4.00 | $4.00 | $4.00 | N/A |
Frequently Asked Questions About SBFM
What is the SBFM stock forecast?
Consensus analyst estimates put Sunshine Biopharma's EPS at -$39.00 for the fiscal year ending Dec 31, 2026, on revenue of $36.75M.
What EPS do analysts expect from SBFM next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$39.00, with estimates from -$39.00 to -$39.00 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$8.00, with estimates from -$8.00 to -$8.00 from 1 analyst.
What revenue do analysts expect from Sunshine Biopharma next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $36.75M, with estimates from $36.75M to $36.75M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $45.00M, with estimates from $45.00M to $45.00M.
How many analysts cover SBFM?
1 analyst estimates EPS for Sunshine Biopharma for the fiscal year ending Dec 31, 2026.
SBFM pages: Overview, Earnings, Forecast, Financials, Competitors